Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of December 2022
Date of Filing: December 30, 2022
Principal Executive Offices: Petach-Tikva, Israel
This filing serves to incorporate by reference a press release dated December 30, 2022, titled "Can-Fite Announces ADS Ratio Change."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce a corporate action rather than a financial report.
Material Changes
- ADS Ratio Change: The company announced a change to its American Depositary Share (ADS) ratio. Specific details regarding the old and new ratios are contained in the attached press release (Exhibit 99.1) but are not explicitly detailed in the body of this Form 6-K.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document focuses solely on the incorporation of the press release regarding the ADS ratio change.
Investor Verification Checklist
- Verify the specific details of the ADS ratio change (e.g., the new ratio and effective date) in the attached Exhibit 99.1 press release.
- Confirm the impact of the ADS ratio change on the number of shares held and the trading price per ADS.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.